The efficacy of low-dose gefitinib for advanced non-small cell lung cancer (NSCLC) with sensitive epidermal growth factor receptor (EGFR) mutations: A post-hoc analysis from NEJ002.
A. Inoue, T. Nukiwa(Tohoku University), Hiroshi Isobe, Satomu Morita, Keigo Kobayashi(Osaka Gakuin University), Makoto Maemondo(Miyagi Prefectural Hospital Organization), Yasuo Saijo(Ho Chi Minh City International University), K. Hagiwara, Satoshi Oizumi(Hokkaido University), Akihiko Gemma(Nippon Medical School)
Cited by 1
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial
|The Lancet Oncology|2019|642
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
|The Lancet Oncology|2018|579